These are the stocks posting the largest moves before the bell.Market Insiderread more
Target beats second-quarter earnings expectations thanks to an increase in traffic and sales. The retailer also boosts its full-year estimates.Retailread more
Corporate debt recently passed the $1 trillion mark in a continuing sign of global financial displacement.Marketsread more
Trump said he has "been thinking about payroll taxes for a long time" — and he cautioned that "whether or not we do something now, it's not being done because of recession."Politicsread more
Lowe's also tops rival Home Depot on same-store sales growth in the U.S.Retailread more
President Donald Trump said on Twitter he was postponing a scheduled meeting with Denmark's prime minister because of her lack of interest in discussing a possible sale of...World Politicsread more
Dow to open higher; strong retail earnings; Gundlach says Fed lost control; negative-yielding corporate debt soars; and Trump on payroll tax cutMarketsread more
After a rush on refinances, homeowners took a breather last week, despite still seeing the lowest interest rates in about three years.Real Estateread more
Toni Sacconaghi said increased competition abroad is responsible for the weakness in Tesla's sales volume.Investingread more
The growing popularity of cocaine cut with fentanyl — known on the street as a speedball — or combinations of methamphetamine and fentanyl — known as a goofball — are driving...Health and Scienceread more
After Elon Musk touts Tesla solar on Twitter, Walmart sues the electric vehicle and clean energy company over store rooftop panels that ignited.Technologyread more
The Senate Finance Committee said Tuesday it invited five major pharmacy benefit managers to testify before Congress about high prescription drug costs in the U.S.
Chairman Chuck Grassley, R-Iowa., and Ron Wyden, D-Ore., the committee's ranking member, asked Cigna, CVS, Humana, OptumRx and Prime Therapeutics to testify on Capitol Hill on April 3. Both senators have been critical of PBMs, sometimes referred to as middlemen, which negotiate drug benefits with manufacturers for insurance plans and employers.
"Middlemen in the health care industry owe patients and taxpayers an explanation of their role. There's far too much bureaucracy and too little transparency getting in the way of affordable, quality health care," Grassley and Wyden said in a joint statement Tuesday. "We've heard from pharmaceutical companies and it's only fair that the committee has the opportunity to ask questions of other players in the health care supply chain."
CNBC has reached out to each company for comment.
High drug costs have become a rare bipartisan issue with lawmakers on both sides of the aisle demanding something be done. President Donald Trump has made lowering prices one of the key issues of his administration. Democrats are jockeying to prove they can lead reform.
Spending on prescription drugs in the U.S. increased to $333.4 billion in 2017, according to the latest data from the Centers for Medicare and Medicaid Services.
The April hearing would mark the committee's third on drug prices this year. Late last month, the committee heard from executives of AbbVie, AstraZeneca, Bristol-Myers Squibb, Johnson & Johnson, Merck, Pfizer and Sanofi.
The pharma executives didn't talk much about list prices. Instead, they blamed middlemen for pocketing discounts instead of passing them along to patients. They suggested changes to Medicare, including capping the amount seniors would pay for on their own at the pharmacy counter every year.
Grassley had hinted last month that the committee's drug pricing probe wouldn't end with pharmaceutical companies.
The nation's four largest PBMs are now all integrated with health insurance firms, following the recent completion of CVS Health's merger with Aetna and Cigna's acquisition of Express Scripts. UnitedHealth Group owns the OptumRX PBM and Anthem will be launching its own unit IngenioRx.